pipeline-prospector-insert-v1
X

Find Drugs for Infections and Infectious Diseases in Phase I Clinical Development

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): INO-4800

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Inovio Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 30, 2020

            Details:

            The goal of this collaboration is to leverage Advaccine's expertise to run a Phase 1 trial in China in parallel with Inovio's clinical development efforts in the U.S.

            National Institutes of Health Clinical Center

            • Development Update

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): mAb CIS43LS

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 27, 2020

            Details:

            The trial, sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ASC22

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 22, 2020

            Details:

            ASC22 is a first-in-class, subcutaneously administered PD-L1 antibody approved for such clinical trials in HBV patients on a global basis.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ibezapolstat

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 15, 2020

            Details:

            United States Adopted Names Council of the American Medical Association has approved the use of ibezapolstat for ACX-362E for the oral treatment of patients with C. difficile Infection.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): TXA709

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Boston University

            Deal Size: $14.6 million Upfront Cash: $3.2 million

            Deal Type: Funding January 14, 2020

            Details:

            Funding aims to develop Efflux Pump Inhibitors (EPIs), representing a new drug class designed to address a major mechanism of multi-drug-resistant (MDR) Pseudomonas aeruginosa bacteria.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Spr 206

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 13, 2020

            Details:

            Analysis of preliminary clinical trial in healthy volunteers suggests that SPR206 is well-tolerated at doses that are likely to be within a therapeutic range for target MDR Gram-negative bacterial infections.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MV-012-968

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2020

            Details:

            With Fast Track Designation, Meissa is eligible for early and frequent interactions with FDA reviewers to discuss all aspects of the clinical development plan for MV-012-968.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Set-point vaccines

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Vickers Venture Partners

            Deal Size: $11.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 09, 2020

            Details:

            The financing will support a first-in-man Phase I clinical trial of its Flavivirus (Dengue) vaccine in Switzerland, as well as Phase Ib clinical trials in the endemic regions of Singapore and Brazil.

            Rockefeller University

            • Deals

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Elipovimab

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 09, 2020

            Details:

            Gilead Sciences, company has licensed The Rockefeller University’s portfolio of broadly neutralizing antibodies (bNAbs) against HIV, including the two clinical-stage agents 3BNC117 and 10-1074.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): GS-9722

            Therapeutic Area: Infections and Infectious Diseases

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: Gilead Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 08, 2020

            Details:

            In this licence agreement, Gilead will access Xencor’s Xtend™ extended half-life and Cytotoxic XmAb® Fc technologies for developing and commercializing GS-9722.

            PharmaCompass